{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.87","value":"-26.6"},{"groupId":"OG001","spread":"27.71","value":"-30.3"},{"groupId":"OG002","spread":"27.65","value":"-31.1"},{"groupId":"OG003","spread":"26.74","value":"-31.6"},{"groupId":"OG004","spread":"26.83","value":"-33.0"},{"groupId":"OG005","spread":"27.58","value":"-32.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"521"},{"groupId":"OG001","value":"479"},{"groupId":"OG002","value":"442"},{"groupId":"OG003","value":"414"},{"groupId":"OG004","value":"387"},{"groupId":"OG005","value":"367"}],"units":"Participants"}],"description":"Patient's global assessment of disease activity is the patient's overall assessment of their disease activity during specified time periods on a 100 mm horizontal visual analogue scale (VAS). The left-hand extreme of the line was described as \"no disease activity\" (symptom-free and no arthritis symptoms) and the right-hand extreme as \"maximum disease activity\" (maximum arthritis disease activity). Change from baseline was calculated for given periods, and a negative change indicates improvement.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with scores at 24 weeks post-baseline.","id":"OG000","title":"Week 24"},{"description":"Participants with scores at 48 weeks post-baseline.","id":"OG001","title":"Week 48"},{"description":"Participants with scores at 108 weeks post-baseline.","id":"OG002","title":"Week 108"},{"description":"Participants with scores at 156 weeks post-baseline.","id":"OG003","title":"Week 156"},{"description":"Participants with scores at 204 weeks post-baseline.","id":"OG004","title":"Week 204"},{"description":"Participants with scores at 264 weeks post-baseline.","id":"OG005","title":"Week 264"}],"paramType":"MEAN","populationDescription":"All exposure population, which includes all participants who entered the study and received at least one dose of tocilizumab at any time, with a score at the given time point.","reportingStatus":"POSTED","timeFrame":"through 264 Weeks","title":"Change From Baseline in Scores for Patient's Global Assessment of Disease Activity Over Time, Through 264 Weeks","type":"SECONDARY","unitOfMeasure":"Units on a Scale"}